Panayiotis Anastasiou

Research Fellow (PostDoc) in Quezada Lab @UCL Cancer Institute

[Roberto Vendramin @RobertVendramin]

🚨Paper alert🚨 Very excited to share our manuscript, published today in @ImmunityCP, where we describe how ‘Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome’. (1/16) https://t.co/S58jZLKZ7G

[Quezada Lab @QuezadaLab]

Come join our team!! https://t.co/aA0YanfGEk

[Waggoner Lab @LabWaggoner]

Not turbo cancer but turbo cancer-immunotherapy!
Combining mRNA COVID vaccines with standard-of-care immune therapy overwhelms tumor defenses to improved survival in animal models and large cohorts of people with cancer @NatureNV
https://t.co/p8AvbZUyya
https://t.co/jqu6xaG8Jl

[Νικόλας Κάιζερ @nickaizer1]

παρά το γεγονος οτι τους επέστησαν την προσοχη, δεν τόλμησαν να μετακινησουν το κέντρο διαχείρισης στον Αγιο Αμβρόσιο, γιατι περίμεναν τον Πρόεδρο και τους διάφορους παρατρεχάμενους του…

[Quezada Lab @QuezadaLab]

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies: https://t.co/EB5a9vTrLO
Amazing collaboration led by @CR_UK funded @QuezadaLab @galvez_cancino @uclcancer and colleagues!

[Julian Downward @JulianDownward]

Happy to report the posting of a new study on compounds that block the interaction of RAS proteins with PI 3-kinase PIK3CA from Vividion Therapeutics @VividionTx, in collaboration with Francis Crick Institute @JulianDownward
https://t.co/9E5SMa6ysy

[Miriam Molina Arcas @molina_arcas]

Really grateful for the invitation to speak at this amazing meeting. Hot Topic Meeting: Tolerance and #Resistance to #TargetedTherapy in #NSCLC @IASLC #HTTR2024

[Michael Fischbach @mfgrp]

Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent antibody response against a pathogen. Could lead to topical vaccines that are applied in a cream. @DjenetBousbaine led the charge... @Nature 1/55

[Julian Downward @JulianDownward]

In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy.
https://t.co/3ErFb9VBpm

[Febe van Maldegem @F_vanMaldegem]

https://t.co/n1B55vWxks

T cells receive regulatory signals from close neighbours, through ligand-receptor interactions and cytokines. Therefore we dived into the local neighbourhoods of CD8 T cells to investigate why a lung cancer model was resistant to KRAS-G12C-i + a-PD1.

[The Francis Crick Institute @TheCrick]

Research from @JulianDownward @Anastap78 and @molina_arcas at the Crick, working with Revolution Medicines, shows that combining treatments can help to eradicate lung tumours in mice.

Read the full story ⤵️
https://t.co/NqEGLHosk9

[Panayiotis Anastasiou @Anastap78]

Excited to share the data from my PhD project!! 🎉 Thank you to all the people that were involved!! 🙏

[Julian Downward @JulianDownward]

How can we extend responses to KRASG12C drugs? Out now in @NatureComms, combining Revolution Medicines’ RAS(ON) G12C-selective inhibitor with a SHP2 inhibitor and immune checkpoint blockade to study their effects on KRAS-mutant lung tumours of varying immunogenicities.

[Elizabeth Lieschke @LizzieLieschke]

Excited to see my PhD work out in the world in @embojournal. Thanks to everyone involved - it wouldn’t have possible without you all!

https://t.co/B1b8rmeODG

[Cancer Research @CR_AACR]

New in #CancerBiology from the July 15 issue—
CRISPR-Cas9 Screening Identifies #KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer, by @jboumelha, @molina_arcas, @JulianDownward, et al.
https://t.co/USClY8OFwv
@TheCrick #openaccess

[Julian Downward @JulianDownward]

How does oncogenic KRAS impact anti-tumor immunity in lung cancer? Out now in @CR_AACR, using CRISPR screening we uncover COX-2/PGE2 signalling as a major mediator of immunotherapy resistance driven by oncogenic KRAS signaling. @jboumelha @TheCrick https://t.co/7gxDlqyao5

[Febe van Maldegem @F_vanMaldegem]

We are recruiting for 3 PhD student positions, investigating different aspects of the lung cancer tumour microenvironment, within the context of an exciting EU collaboration! Great facilities & great teams! 🔬
https://t.co/VGvZ7vQTcN

Apply before 6th July!

[Julian Downward @JulianDownward]

We are looking for a post-doc with a background in immunology to work on the impact of RAS oncogenic signaling on the interaction of lung cancers with the immune system. Fully funded four year position at Francis Crick Institute in London. #Crick https://t.co/RFbqyRoLft

[Miriam Molina Arcas @molina_arcas]

Fantastic opportunity to join the #downwardlab! Great science with amazing people. I couldn’t recommend it more (a bit biased here). Please share!

[Julian Downward @JulianDownward]

Just published in @CellReports #OpenAccess. We show that the palmitoyl transferase ZDHHC20 mediates metastasis of pancreatic cancer in vivo. https://t.co/vEOuZ5h3yk

[Febe van Maldegem @F_vanMaldegem]

Local T cell neighbourhoods determine outcome in non-small cell lung cancer treatment with KRAS-G12C inhibitors.

Timely and relevant work from Megan Cole and @Anastap78 from the @JulianDownwardlab, and @claudialee_ from the @SwantonLab.
https://t.co/9MXgB8ImS1